FDA grants priority review vouchers to Otsuka, Compass Pathways, and Usona for psychedelic-related therapies

Priority Review Vouchers from the US FDA are being awarded to Otsuka, Compass Pathways, and Usona, linked to their development programs in psychedelic-related medicine. The update frames how Priority Review Vouchers can speed FDA review timelines and potentially accelerate patient access once clinical evidence supports approval. It also highlights the companies involved and positions the awards within the broader push to bring novel psychiatric and therapeutic options to market. Overall, the news centers on regulatory incentives as a mechanism that can reduce review delays and increase momentum for psychedelic therapeutics in the United States.